1 Microvascular insulin resistance associates with enhanced muscle glucose disposal in 2 CD36 deficiency.

- 3
- 4 Cyndya Shibao^{1 #}, Vivek S. Peche², Ian M. Williams³, Dmitri Samovski², Terri A. Pietka², Naji N.
- 5 Abumrad⁴, Eric Gamazon⁵, Ira J. Goldberg⁶, David Wasserman³, Nada A. Abumrad.^{2, 7 #}
- 6
- ⁷ ¹Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center,
- 8 Nashville TN.
- 9 ²Department of Medicine, Division of Nutritional Sciences and Obesity Research, Washington
- 10 University School of Medicine, St. Louis, MO.
- ¹¹ ³Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center,
- 12 Nashville TN
- ⁴Department of Surgery, Vanderbilt University Medical Center, Nashville TN.
- ⁵Department of Medicine, Division of Genetic Medicine, Vanderbilt University, Nashville, TN
- ¹⁵ ⁶Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, New York
- 16 University Grossman School of Medicine, New York, NY
- ¹⁷ ⁷Department of Cell Biology & Physiology, Washington University School of Medicine, St. Louis,
- 18 MO.
- 19
- 20 Abbreviated title: Microvascular and muscle insulin sensitivity
- 21 Key words: Endothelial function, microvascular circulation, nitric oxide, African Americans,
- 22 23
- Word count: 6384 Number of tables: 2 Number of figures: 5
- 24
- 25 Correspondence:
- 26 Cyndya Shibao, MD, M.S.C.I.
- 27 2220 Pierce Avenue
- 28 506 Robinson Research Building
- 29 Nashville, TN 37232
- 30 <u>cyndya.shibao@vumc.org</u>
- 31
- 32 Nada A Abumrad, PhD
- 33 Washington University School of Medicine
- 34 660 S Euclid Avenue
- 35 Campus Box 8031
- 36 St Louis, MO 63110
- 37 <u>nabumrad@wustl.edu</u>
- 38
- 39

40 Abstract

41 Dysfunction of endothelial insulin delivery to muscle associates with insulin resistance. CD36, a 42 fatty acid transporter and modulator of insulin signaling is abundant in endothelial cells, especially 43 in capillaries. Humans with inherited 50% reduction in CD36 expression have endothelial 44 dysfunction but whether it is associated with insulin resistance is unclear. Using hyperinsulinemic/euglycemic clamps in Cd36^{-/-} and wildtype mice, and in 50% CD36 deficient 45 humans and matched controls we found that $Cd36^{-/-}$ mice have enhanced systemic glucose 46 47 disposal despite unaltered transendothelial insulin transfer and reductions in microvascular 48 perfusion and blood vessel compliance. Partially CD36 deficient humans also have better glucose 49 disposal than controls with no capillary recruitment by insulin. CD36 knockdown in primary human-50 derived microvascular cells impairs insulin action on AKT, endothelial nitric oxide synthase, and 51 nitric oxide release. Thus, insulin resistance of microvascular function in CD36 deficiency 52 paradoxically associates with increased glucose utilization, likely through a remodeling of muscle 53 gene expression. 54

- 54
- 55
- 56

57 Introduction

58 The membrane fatty acid (FA) transporter CD36 was initially identified as an insulin 59 resistance gene when CD36 sequence variants were found in the insulin-resistant spontaneously 60 hypertensive rat (SHR) a model of type 2 diabetes (T2D). Transgenic CD36 expression ameliorated 61 the defect in FA metabolism and insulin resistance of the SHR (1, 2). In humans a C/T single 62 nucleotide polymorphism (SNP rs1527479) in the CD36 promoter associates with insulin resistance 63 and T2D (3), a rare nonsense mutation (rs56381858) in a Caucasian pedigree is linked to 64 autosomal dominant T2D (4). Our genome-wide association analysis of available data from the 65 Vanderbilt BioVu patient biobank and the MAGIC Consortium show that reduced CD36 expression 66 in muscle and heart, and a SNP (rs17236824) within 1 MB of the transcription start site, associated 67 with T2D renal, ophthalmic, and neurological complications (5). In addition, a common CD36 68 haplotype is associated with T2D-linked coronary heart disease (6). The mechanisms underlying 69 the T2D-related metabolic alterations that are associated with CD36 variants remain unclear.

70 Complete CD36 deficiency has a prevalence of 0.3–11% with higher incidences in populations 71 of Asian and African descent (7, 8). CD36 coding SNP rs3211938 (G/T) is the major cause of 72 deficiency in African Americans and carriers of the minor G allele (frequency 20-25%) have 50% 73 reduction of CD36 levels (9, 10). Although deficiency is low in Caucasians (0.3%) SNPs that reduce 74 CD36 levels are common (11). Information on whether insulin sensitivity is altered in individuals 75 with partial or total CD36 deficiency is limited. Only few studies evaluated whole-body glucose 76 disposal in small cohorts of these subjects and reported conflicting results (12-14). Studies in mice 77 suggest a complex relationship between CD36 expression and insulin sensitivity. Cd36^{-/-} mice have 78 enhanced systemic glucose disposal, consistent with better muscle insulin sensitivity (15), however 79 this enhancement is not recapitulated by CD36 deletion in muscle (5). CD36 knockdown in cultured 80 human myotubes impairs insulin signaling, as CD36 promotes tyrosine phosphorylation of the 81 insulin receptor (IR) by Fyn kinase and enhances IR signaling to AKT (5). Surprisingly, in contrast 82 to the effect of muscle CD36 deletion, endothelial cell (EC) specific deletion enhances systemic 83 glucose disposal (16) mimicking the $Cd36^{-4}$ mouse phenotype (16). These data can be interpreted 84 to indicate that muscle glucose disposal is critically influenced by endothelial CD36. In the present 85 study we interrogated some of the underlying mechanisms and their potential relevance to humans.

The vasculature is the most important regulator of nutrient exchange and dysfunction of microvessels can alter muscle access to circulating insulin and glucose (17, 18). Strong evidence supports importance of vascular insulin action in regulating muscle glucose disposal (19, 20). For example the endothelial dysfunction that associates with obesity causes a delay in insulin action to increase peripheral blood flow, and correlates with reduced whole body glucose uptake (21). We

91 previously described reduced flow mediated dilation of the brachial artery and low cGMP levels in 92 subjects carrying the G-allele of CD36 coding SNP rs3211938, suggesting reduced nitric oxide (NO) 93 bioavailability (9). In this study we used metabolic insulin clamps to assess insulin sensitivity of 94 glucose disposal in $Cd36^{-/-}$ mice, and in 50% CD36 deficient human carriers of the G-allele of SNP 95 rs3211938, we examined the relationship between microvascular function, transendothelial insulin 96 flux and muscle glucose uptake.

97

98 Methods

99 Mice Experimental Protocols

100 Mice studies used age-matched 3-4 months old wild-type (WT) and *Cd36^{-/-}* mice on the C57BL/6 101 background. Male and female mice were used except when indicated. Experimental protocols were 102 approved by the Animal Studies Committees of Washington University or Vanderbilt University.

103 Vessel Compliance: Ascending aortas and left carotid arteries (from transverse aorta to 6 104 mm up the common carotid) were dissected from euthanized WT and $Cd36^{-1}$ mice as previously 105 described (22, 23). Briefly, vessels mounted in physiological saline on a pressure arteriograph 106 (Danish Myotechnology, Copenhagen), were pressurized and longitudinally stretched to in vivo 107 length three times before data capture. Vessel diameter recordings used a transillumination 108 microscope connected to a camera and a computerized measurement system (Myoview, Danish 109 Myotechnology). Intravascular pressure was increased from 0 to 175 mmHg in 25-mmHg steps and 110 the vessel's outer diameter (OD) was measured at each step.

Muscle insulin sensitivity in vivo: 5 hour fasted mice were injected with intraperitoneal insulin (0.75 units/kg) and tissues harvested 15 min later were quickly frozen in liquid nitrogen and kept at -80°C until used for western blots as previously described (5). Antibodies used: anti-mouse CD36 (R&D Systems, AF1955), anti-pS473-Akt (Cell Signal Technology, 4060), anti-pT308-Akt (Cell Signal Technology, 13038) and total Akt (Cell Signal Technology, 4691).

116 Transcapillary Insulin Flux: Intravital microscopy (IVM) of the exposed gastrocnemius was 117 used to visualize transcapillary insulin flux in WT and Cd36^{-/-} mice. Insulin was conjugated to Alexa 118 Fluor 647 and the probe tested to ensure purity and bioactivity comparable to unconjugated insulin 119 as previously described (24). Prior to IVM, the probe was mixed vigorously in saline, sonicated 1 120 hour, centrifuged (20 min, 13000 rpm) to remove insoluble material and microscopically inspected 121 for absence of aggregates (24). The mice were anesthetized with ketamine/xylazine/acepromazine 122 (7.9/1.6/0.2 mg/kg) via an indwelling venous catheter, placed on a heated pad. Skin of the shaved 123 lower leg was removed to expose the lateral gastrocnemius and peel off its fascia avoiding 124 perturbation of muscle fibers and blood vessels (24). For imaging the mouse was transferred to the custom stage mount and its body temperature kept at 37°C through a feedback control system connected to an electric blanket (Harvard Apparatus). To keep hydration and physiological stability of the gastrocnemius it was continuously irrigated with bicarbonate-buffered physiological saline solution (PSS); in mmol/L 132 NaCl, 4.7 KCl, 2 MgSO₄, 1.2 CaCl₂, and 18 NaHCO₃. PSS kept at 37°C was bubbled with 95%N₂/5%CO₂ to maintain a 7.4 pH and continuously circulated over the tissue using a peristaltic pump (inflow) and a vacuum trap (outflow) (24).

131 Quality of the gastrocnemius preparation was visualized using tissue autofluorescence with 132 light from a 120W mercury arc lamp (XCite[®] 120) sent through a bandpass filter (Zeiss Filter Set 133 10; Excitation: 450-490nm, FT: 510nm, Emission: 515-565nm) onto the exposed region. To 134 visualize blood vessels the mouse was infused with 50 µg of 2 MDa rhodamine-dextran (rho-dex) 135 and the filter set switched (Zeiss Filter Set 43 HE; Excitation: 550/25nm, FT:570nm, Emission: BP 136 605/70). The field of view was selected from a capillary bed stemming from the external sural artery 137 based on 1) presence of a sufficient number of clearly visible capillaries; 2) absence of large vessels 138 in nearby area; and 3) absence of capillaries immediately adjacent to one another.

139 Intravital microscopy used an inverted Zeiss LSM 780 microscope (Zen software) with a 20X 140 0.8NA Plan-Apochromat air objective. For imaging transendothelial molecular flux (ins-647, BSA-141 647, dextrans), rho-dex fluorescence was excited with light from a 561 nm solid-state laser and 142 detected on a multichannel PMT. Near-infrared fluorophores were excited by a helium-neon 633nm 143 laser and emitted light detected with a gallium arsenide phosphide semiconductor. For both rho-144 dex and near-infrared fluorophores, excitation and emission light were reflected with an MBS 145 488/561/633 dichroic mirror and imaging used two-channel sequential excitation and detection to 146 avoid bleed through, in an optical section of 8 μ m (+/- 4 μ m about the focal plane). The 8-bit intensity, 147 1024x1024 pixel images were acquired with unidirectional scanning. For each time point, a 4-"slice" 148 z-stack was acquired in each channel using a 4µm step size to avoid aliasing. Photomultiplier tube 149 settings were adjusted to maximize image dynamic range and kept constant for each experiment 150 for quantitative comparisons. The imaging region was selected, a background image (t=0) was 151 acquired then probe (rho-dex and ins-647) was injected through the venous catheter and images 152 acquired every minute at t=1-10, at 12.5 and 15 min, post probe injection (24).

Hyperinsulinemic-euglycemic Insulin Clamp: Catheters were implanted under isoflurane anesthesia in the carotid artery for sampling and jugular vein for infusion a week before performing clamps (25) to allow the mice to regain weight lost due to surgery. The mice were fasted for 5h before the clamp and not restrained or handled during the experiments (26). [3-³H]glucose was primed and continuously infused from *t*=-90min to *t*=0min (0.04 μ Ci/min). The insulin clamp was initiated at *t*=0 min with a continuous insulin infusion (4 mU·kg⁻¹·min⁻¹) and a variable glucose

159 infusion rate (GIR), both maintained until t=155 min. Infused glucose had 0.06 µCi/µL [3-3H]-glucose 160 to minimize changes in plasma [3-3H]-glucose specific activity. Arterial glucose was measured every 161 10 min and GIR adjusted to maintain euglycemia. Erythrocytes were infused to compensate for 162 withdrawn blood. [3-3H]-glucose kinetics were determined at -15 min and -5 min (basal period) and 163 every 10 min between 80-120 min to assess whole-body glucose appearance (Ra), disappearance 164 (R_d), and endogenous glucose production (endoR_a). For tissue-specific index of glucose uptake 165 (Rg) intravenous 13 µCi 2-[¹⁴C]-deoxyglucose ([¹⁴C]2DG) was given at 120 min and blood samples 166 collected at 122, 125, 135, 145 and 155 min to assess [14C]2DG plasma disappearance. Plasma 167 [3-³H]-glucose and [¹⁴C]2DG, and tissue [¹⁴C]2DG-phosphate were measured as previously (27). 168 At 155 min, the mice were anesthetized, and harvested tissues freeze clamped. Protocol details 169 are available online at the Vanderbilt Mouse Metabolic Phenotyping Center (www.vmmpc.org).

170 RNAseg and Microarray. For RNA seg human microvascular cells were treated with either 171 control or CD36 siRNA and 72 h later total RNA isolated (TRIzol Reagent, ThermoFisher Scientific), 172 and cleaned (RNeasy, Qiagen). Samples were submitted to the Washington University Genome 173 Technology Access Center (GTAC) for library preparation, sequencing and read alignment. 174 Normalization and differential gene expression used the integrated Differential Expression and 175 Pathway Analysis (iDEP) web platform (28). For microarrays total RNA (TRIzol) isolated from heart 176 of 4h fasted mice was analyzed using Whole Mouse Genome Oligo Microarray (Agilent Technology, 177 Santa Clara, CA) at the Washington University Functional Genomics Core of the Digestive Disease 178 Research Center.

179 Human Study Protocols

180 Subjects: Healthy unrelated African American men and women, between the ages of 18-50 181 vears old were recruited and genotyped for the CD36 coding single nucleotide polymorphism (SNP) 182 rs3211938 (G/T). This SNP, which reflects positive selection pressure, is almost exclusive to 183 populations of African ancestry (where G-allele incidence is 20-25%) (9). The SNP inserts a stop 184 codon resulting in a truncated protein that is degraded. Partial CD36 protein deficiency is observed 185 in subjects carrying the G allele and complete deficiency is observed in subjects who are 186 homozygous (G/G) (10). Subjects were excluded from participating in the study for the following: 187 BMI>40 kg/m², type 1 or 2 diabetes mellitus, cardiovascular disease including hypertension, 188 impaired renal or liver function, use of nitrates, or systemic glucocorticoid therapy. Participants 189 reported to the Vanderbilt Clinical Research Center (CRC) for pre-screening and blood collection. 190 DNA was extracted, genotyped for rs3211938, and G-allele carriers and noncarriers invited to a 191 screening visit for a medical history, physical exam, and laboratory analyses (blood cell count, 192 metabolic panel, pregnancy test).

193 Genomic DNA was extracted from peripheral blood with a salting-out precipitation (Gentra 194 Puregene) and CD36 SNP rs3211938 detected using a predesigned TaqMan SNP genotyping 195 assay (Applied Biosystems) on a 7500 Fast (Applied Biosystems) instrument. Previous studies have 196 identified that the rs3211938 G allele reduces CD36 expression by 50% (9, 10). All human 197 assessments and studies were performed at the Vanderbilt CRC at 8 am in a quiet, temperature-198 controlled room (22 to 23 °C). Participants were asked not to exercise or drink alcohol for at least 199 24 hours before the study and were contacted by the research nurse to remind them to fast the 200 night before. All participants underwent two visits at least 2 weeks apart. All studies adhered to 201 principles of the Declaration of Helsinki and Title 45 of the US Code of Federal Regulations (Part 202 46, Protection of Human Subjects). Studies were approved by the Vanderbilt Institutional Review 203 Board and conducted in accordance with institutional guidelines. All subjects provided informed 204 consent. The study was included in clinicaltrials.gov, identifier: NCT03012386

Hyperinsulinemic-euglycemic (Insulin) Clamp: During each visit, two intravenous (IV) catheters were placed in the antecubital fossa of each arm. One of the catheters was used for drug infusion, the other one for blood collection. A linear-array transducer connected to an ultrasound was placed on the brachioradialis muscle of the arm not used for infusion. The transducer was used to measure changes in microvascular circulation with contrast-enhanced ultrasonography (CEU) and remained in the same position throughout the study.

211 On the first study day (saline day), participants received 0.9% standard saline infusion 212 (45ml/h) for 6 hours, and during the last three hours, a hyperinsulinemic-euglycemic (HIE) clamp. 213 Insulin was infused at a rate of 80 mU·m⁻²·min⁻¹ for 5 min followed by 40 mU·m⁻²·min⁻¹ for the 214 remainder of the study. Plasma glucose samples were obtained every 5 minutes throughout the 215 clamp and 5% glucose was infused at a variable rate to maintain plasma glucose between 90 to 95 216 mg/dl. Blood samples were collected for assay of plasma insulin.

The second study day was ~4 weeks later. Participants returned to the CRC and instead of saline received a 6-hour IV infusion of 20% Intralipid[®] (Baxter Healthcare Crop. Glendale, CA) at a rate of 45 ml/h and heparin (200 units prime followed by 200 units/hr.). Heparin was used to activate endothelial lipoprotein lipase and accelerate lipolysis of triglycerides into fatty acids. The HIE clamp was conducting during the last three hours of the study.

In both day visits, CEU measurements were obtained 3 hours after initiation of infusions (saline or Intralipid[®] and heparin) during the insulin clamp. Intermittent blood pressures and ECG were measured using the VITAL-GUARD 450c monitor (Ivy Biomedical Systems, Branford, CT). Vanderbilt's Investigational Pharmacy conducted drug preparation, storage, and dispensing logs. 226 Assessment of microvascular blood volume index: Contrast-enhanced ultrasound imaging 227 used a linear-array transducer connected to an ultrasound (L9-3 mm transducer, iU22; Phillips). 228 Real-time imaging used low (0.08) and high (1.2) mechanical index. The contrast microbubbles 229 (Definity, Bristol-Myers Squibb) were infused at 1.5 ml/min for 10 min. At steady state (~4 min), the 230 1.2 mechanical index destroyed the microbubbles at the start of video recording. Switch to the low 231 index (0.08) made microbubbles resonate allowing real-time recording of vascular replenishment. 232 Local temperature was measured with a laser Non-Contact Infrared Skin Thermometer. Data were 233 analyzed using QLAB software.

234 *Clinical Chemistry:* Blood collected in chilled EDTA tubes was immediately centrifuged and 235 separated plasma stored at -80°C. For serum, blood clotted at room temperature for 20 minutes 236 was centrifuged and removed serum stored at -80°C. Plasma glucose was measured with a 237 glucose analyzer (YSI Life Sciences, Yellow Springs, OH). Plasma insulin concentrations were 238 determined by radioimmunoassay (Millipore, St. Charles, MO).

239 Human microvascular cells (hMEC) protocols

240 CD36 knockdown, Caveolin 1-eNOS interaction: Human derived primary dermal 241 microvascular cells, hMEC, (Lonza bioscience) were cultured in EGM-2 MV endothelial media 242 (Lonza) and passaged less than 5 times. Cells were treated with siRNA against CD36 (4392420, 243 assay ID 2646, ThermoFisher Scientific) or with control siRNA for 72 hours, as previously described 244 (28). The hMEC were serum starved for 4 h before adding human insulin (100nM, Sigma) for the 245 indicated times. For western blots, cells were lysed 20 min in ice-cold RIPA buffer (20 mM Tris-HCl, 246 pH 7.5, 150 mM NaCl, 1mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM 247 sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1µg/mL leupeptin, 1mM 248 PMSF, and 1µg/mL protease inhibitor mix). Cleared lysates (10,000 x g, 10 min) were assayed for 249 protein content (DC Protein Assay, Bio-Rad). Separated proteins (30 µg, 4%–20% gradient gels, 250 ThermoFisher Scientific) were transferred to polyvinylidene membranes (Immobilon FI, Millipore), 251 blocked (1X TBS, 0.25% fish gelatin, 0.01 % Na-azide, 0.05% Tween-20) and primary antibodies 252 added overnight at 4°C. Washed membranes were treated 1h with infrared dye-labeled secondary 253 antibodies (RT, LI-COR Biosciences) and imaged (LI-COR Odyssey Infrared). Primary antibodies 254 used: anti-human CD36 (R&D Systems, AF2519), anti-pS473-Akt (Cell Signal Technology, 4060), 255 total Akt (Cell Signal Technology, 4691), pS1177-eNOS (Cell Signal Technology, 9571), total-eNOS 256 (Cell Signal Technology, 32027) and beta-Actin (Santa Cruz Biotechnology, sc-47778). 257 For immunoprecipitation (IP) 4h serum-starved hMECs were treated with insulin (100nM

Por immunoprecipitation (IP) 4n serum-starved nideCs were treated with insulin (100nm)
 10min, 37°C) then washed cells were scraped into 1 ml IP buffer (0.1 M NaCl, 0.3 M Sucrose, 30mM)
 MgCl2, 10 mM PIPES, 0. 5mM EDTA, 0.1% Nonidet P-40, protease and phosphatase inhibitors

and 0.5 mM pervanadate) kept on ice 20 min, then lysed by passage 5 times through a 25-gauge
needle. Aliquots (50 µg protein) of clarified (11,000 x g, 10 min) lysates were incubated 5h with
Cav-1 antibody (Cell Signaling Technology, 3238) coupled to protein G magnetic beads
(Dynabeads, ThermoFisher). Rabbit IgG-coupled beads were controls. Immune complexes were
separated magnetically, washed (IP buffer) and boiled in 50µL of 2X SDS-Sample buffer prior to
SDS-PAGE (4-12%).

- 266 *Nitric Oxide measurement:* The Nitrate/Nitrite Colorimetric Assay (Cayman Chemicals,
- 267 780001) was used. Human insulin (Sigma, I9278) was added (100nM, 10 min) to 4 h serum
- starved cells and media collected for NO measurement as per the manufacturer's protocol.

269 **Biostatistics**

270 Data are presented as means ± standard errors of the mean (SEM). Data were log-transformed

271 prior to statistical testing when not normally distributed by the Shapiro–Wilks test. Summary data

- were analyzed by a paired, parametric, two-tailed Student t test. P values of <0.05 were considered
- 273 significant (****P≤0.0001, ***P≤0.001, **P≤0.01, *P≤0.05, ns P>0.05). All analyses used Prism
- 10.0 (GraphPad Software, La Jolla, CA).
- 275

276 **Results**

277 CD36^{-/-} mice have enhanced systemic glucose disposal and muscle insulin signaling.

278 Hyperinsulinemic glucose clamps were performed in mice following a 5 h fast and a period 279 of basal sampling. Cd36^{-/-} mice have slightly smaller body weight than WT mice (**Fig. 1A**), on average around 8% with similar lean body mass (29). Under basal conditions, plasma 280 insulin was similar for WT and $Cd36^{-/-}$ mice but the latter group had lower arterial glucose, 281 282 in line with earlier studies (15, 16). Clamping glucose during equivalent hyperinsulinemia 283 required a significantly higher GIR in Cd36^{-/-} than in WT (Fig. 1B, C, D). Whole body rate 284 of disposal (Rd) was increased during the clamp in $Cd36^{-/-}$ compared to WT mice (Fig. 1E) 285 and the $Cd36^{-/-}$ mice displayed greater % suppression of endogenous rate of appearance 286 (Ra) during the insulin clamp (85% versus 59%) (Fig. 1F). The delta and percent suppression of Ra were both significant. The absolute Ra was close to being significant 287 <0.069 and lower Ra contributes to GIR. The estimated contribution of Rd and Ra to the 288 289 greater GIR was respectively 2:1.

As compared to WT mice, *Cd36^{-/-}* mice had higher glucose uptake (Rg) in leg skeletal muscle (superficial vastus lateralis and soleus) as well as in brown and

subcutaneous white adipose tissues. Glucose uptake by the heart and gastrocnemius trended higher but did not reach significance (**Fig. 1G, H**). The hyperinsulinemic glucose clamp data support the interpretation that CD36 deletion improves insulin-stimulated glucose disposal through increases in Rd and in insulin suppression of endogenous Ra.

296 Muscle insulin signaling is enhanced in Cd36^{-/-} mice: The enhanced insulin stimulated systemic glucose disposal observed in $Cd36^{-/-}$ mice (Figure 1) is not 297 298 recapitulated in mice with muscle or cardiomyocyte specific CD36 deletion, which associate 299 with reduced expression of insulin signaling and glucose metabolism genes in muscle and 300 heart (5, 16). CD36 knockdown in cultured muscle cells also suppresses insulin action to 301 activate AKT by removing CD36 enhancement of insulin receptor phosphorylation and 302 signaling (5). We examined insulin activation of AKT in muscle of Cd36^{-/-} mice to determine 303 if it correlates with the enhanced glucose disappearance observed in these mice during the insulin clamp. First, we confirmed as shown earlier (15) that Cd36^{-/-} mice as compared to 304 305 wildtype (WT) controls have enhanced glucose tolerance and are protected from glucose 306 intolerance induced by a high fat diet (HFD; 60% fat and 7% sucrose) (Fig 2A, B, C), ruling 307 out alterations in insulin action due to changes in mice environment or breeding. Insulin 308 signaling was assessed in muscle of 5h fasted WT and Cd36^{-/-} mice given 0.75 U/kg insulin 309 or saline (controls) intraperitoneally (IP). The mixed fiber quadriceps muscle was harvested 310 15 min after insulin injection and tissue lysates probed for AKT, pAKT and CD36. Muscles of Cd36^{-/-} mice have similar basal AKT^{S473} and AKT^{T308} phosphorylation levels as WT mice 311 312 but a greatly enhanced insulin-stimulated AKT phosphorylation (~7 fold as compared to ~3 313 fold in WT) with no change in total AKT (Fig. 2D, E,F) consistent with enhanced muscle 314 insulin signaling and with the findings from the insulin clamp experiments.

315 We previously reported in 5h fasted Cd36^{-/-} mice significantly enhanced [¹⁸F]-316 Fluorodeoxyglucose (2-FDG) uptake by various muscles. The fold increase over WT was 317 5 for heart, 4 for soleus, 3 for diaphragm and gastrocnemius and 2 for hindlimb (15). 318 Glycogen and triglyceride levels were reduced in heart and muscle. Examination of gene 319 expression in hearts from 5h fasted mice showed upregulation of genes that function in 320 insulin signaling or glucose utilization (Fig. 2G). Increased expression of Glut4 (Slc24, 1.8fold), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (Pfkfb2), which regulates 321 322 glycolytic flux (2-fold), so is expression of hypoxia inducing factor HIF3a (2.6-fold) which

323 upregulates Pfkfb2 (30) and of glycogen synthase (Gys1, 4-fold) and Glycogen 324 phosphorylase (Pygm, 1.9-fold), which regulate glycogen turnover. Expression of PI3K, the pathway that mediates insulin effects on glucose metabolism (pik3c2a and pik3cg) was 1.7-325 326 fold higher, those of AKT2 (1.5-fold), AKT1 (1.45-fold) and AKT1 substrate 1 (2.3-fold). In 327 addition, fibroblast growth factor receptor 1(FGFr1) a major target of FGF and potent 328 stimulator of glucose metabolism in muscle (31) is increased 1.9-fold, insulin like growth 329 factor receptor 1 (IGFR1), which binds IGF, and insulin is up 1.7-fold. Several integrins 330 (ITG) are upregulated. Integrins interact with the extracellular matrix and maintain cell 331 attachment, survival and growth by regulating the signaling of PI3K/AKT, growth factors 332 (FGF, IGF) and Src kinases (32). In addition to a 4.7-fold upregulation of ITGa7 (Figure 333 2G), there were increases in expression of ITGa9, 4.7-fold, ITGa5, 3-fold, and ITGa3, 2.3-334 fold (data not shown). ITGA7/beta1 is the primary receptor for basement membrane laminin 335 in skeletal and heart myofibers and is important in regulating myofiber survival (33, 34). Expression of Janus Kinase 3 (JAK3) which stimulates AKT-independent glucose uptake 336 (35) increased 3-fold Figure 2G. 337

338 *Cd36^{-/-}* mice have normal transendothelial insulin flux but vascular dysfunction.

Insulin Flux: Insulin access to muscle cells is regulated by the capillary endothelium, 339 340 which limits the rate of glucose disposal (19, 20). We examined whether CD36 deletion might affect transendothelial insulin transport (EIT). To investigate this, we used the 341 342 exposed gastrocnemius preparation and intravital imaging of fluorescent insulin-647 (INS-647) as described under methods and in greater detail previously (24). Plasma INS-647 343 dispersion to pericapillary interstitium was unaltered in Cd36^{-/-} mice. Plasma (Fig. 3A) and 344 interstitial INS-647 (Fig. 3B) was similar for Cd36^{/-} and WT mice. The decrease in ratio of 345 plasma INS-647/interstitial INS-647, which measures rate of transfer of capillary insulin with 346 347 interstitial insulin was identical in both groups (Fig. 3C) with gradient decay constants of 348 ~0.15 min⁻¹ (**Fig. 3D**). These data indicate that transendothelial insulin flux is not altered in Cd36^{-/-} mice and did not contribute to the enhanced insulin stimulated glucose disposal. 349

350 *Capillary diameter and perfused area*: Fluorescence of rhodamine-dextran was used 351 to determine the capillary diameter (distance between glycocalyx on opposing endothelium) 352 and the perfused capillary cross sectional surface area. Capillary diameter (**Fig. 3E**) and 353 the perfused capillary surface area (**Fig. 3F**) are reduced by ~15 and ~30%, respectively,

in Cd36^{-/-} as compared to WT mice. The decrease in perfused capillary surface area is 354 unexpected considering the increased insulin action in $Cd36^{-/-}$ mice. To confirm this finding, 355 we examined changes in microvascular perfusion in $Cd36^{-1}$ mice using another organ and 356 357 a different method. Arterial Spin Labeling Magnetic Resonance Imaging (ASL-MRI), a non-358 invasive, guantitative measure of microvascular tissue perfusion (36) was used to estimate 359 renal perfusion. The ASL-MRI data (n=5 mice/group) collected at baseline under 360 anesthesia (1% isoflurane in 100% O2) using a flow-sensitive (FAIR)-type ASL-MRI protocol (37) revealed a 34% deficit (p<0.05) in capillary renal perfusion in $Cd36^{4-}$ mice 361 (p<0.05) (data not shown) confirming the observation (**Fig. 3F**). 362

Vessel compliance: The increase in diameter of the carotid and aorta arteries in response to increased intravascular pressure was examined for *Cd36^{-/-}* mice and WT controls. Vessels from *Cd36^{-/-}* mice as compared to those from WT mice showed reduced dilation as intravascular pressure increased from 0 to 175 mmHg in 25-mmHg steps (**Fig. 3G**). Thus, reduced vessel compliance might have contributed to measurements of smaller capillary diameter and reduced capillary perfused surface area in *Cd36^{-/-}* mice.

In summary insulin action on glucose uptake by muscle is enhanced in $Cd36^{4-}$ mice but this enhancement is independent of microvascular adaptations that improve insulin delivery. Transcapillary flux of insulin is normal in $Cd36^{4-}$ mice, however there is evidence of endothelial dysfunction manifested by a diminished perfused capillary area and reduced vessel compliance. Although endothelial dysfunction normally associates with diminished glucose disposal, paradoxically in the case of CD36 deficiency it coexists with a higher insulin stimulated glucose disposal.

Individuals with partial CD36 deficiency have enhanced insulin response of glucose disposal but microvascular insulin resistance.

Common SNPs that reduce CD36 protein have been identified in many populations including African Americans (38) and Caucasians (10). Carriers of the G-allele of coding SNP 3211938 have 50% of normal CD36 levels (9, 38). We previously reported on presence of endothelial dysfunction in these individuals (9) but there is no information on whether this associates with improved or compromised insulin sensitivity.

383 *Demographic Characteristics of subjects*: Thirty-five subjects were screened, 384 fourteen were excluded for not meeting inclusion criteria or withdrew consent, and twenty385 one completed the study. Participants were divided into two groups based on the CD36 rs3211938 genotype. Controls (n=13) were homozygous for the major allele (T/T) and have 386 387 normal CD36 expression, whereas carriers (n=8) of the minor allele G (G/T) have \sim 50% 388 reduced CD36 expression (9, 10, 38). Only one subject was homozygous (G/G) with 100% 389 reduced CD36 expression and was included with the G/T cohort. The G-allele carriers were 390 on average 8 year older than non-carriers and their average weight trended lower. Fasting 391 glucose and triglyceride levels were similar. No participants were hypertensive; systolic 392 (SBP) and diastolic blood pressure (DBP) were similar. All participants were healthy and 393 not taking medications except for birth control in women (**Table 1**).

Insulin fails to increase microvascular blood volume in G-allele carriers: We examined insulin recruitment of the microvasculature in rs3211938 G-allele carriers (G/T) and control non-carriers (T/T). In non-carriers insulin increased microvascular blood volume index (MBV_i) from 8.4±0.63 to 11.3±1.37 (35%, p=0.05). In contrast, no insulin-induced increase occurred in G-allele carriers (G/T) (**Fig. 4A**). Intralipid infusion instead of saline before the hyperinsulinemic clamp blunted insulin's effect on microvascular recruitment in non-carriers and G-carriers remained unresponsive (**Fig. 4B**).

401 Enhanced whole body insulin sensitivity in G-allele carriers versus non-carriers: 402 CD36 SNPs have been linked to the metabolic syndrome and T2D, but there is no definitive 403 data on whether CD36 deficient subjects are insulin sensitive or resistant. We determined 404 the glucose infusion rate (GIR) in both groups (G-allele carriers and noncarriers) during a 405 continuous insulin infusion at a dose of 40 mU/m²/min. The G-allele carriers required 1.9-406 fold higher GIR than non-carriers, indicating they were more insulin sensitive (Fig. 4C). 407 Intralipid infusion decreased GIR in both carriers and non-carriers and the G-allele carriers 408 were no longer more insulin sensitive as compared to non-carriers (Fig. 4D). The increased 409 GIR in G-allele carriers during saline infusion did not reflect differences in insulin levels 410 during the steady state phase of the clamp (Fig. 4E) and similar insulin concentrations were 411 also measured during the intralipid infusion (Fig. 4F).

In summary the insulin clamp findings indicate enhanced GIR supporting better insulin stimulated glucose utilization in G-allele carriers. This enhancement occurs without insulin stimulation of MVB flow, which suggests insulin resistance of the microvasculature in individuals with partial CD36 deficiency.

416 CD36 knockdown in human microvascular cells impairs insulin action and eNOS 417 activation.

Signaling by insulin contributes to active maintenance of blood vessels through regulated production of NO by endothelial nitric oxide synthase (eNOS) and polymorphisms in eNOS associate with insulin resistance and T2D (39). To gain insight into the mechanism of the microvascular insulin resistance in G-allele carriers, we investigated role of CD36 in insulin regulation of eNOS using primary human-derived microvascular endothelial cells, hMEC, which express high levels of CD36, a microvascular signature gene (28, 40).

CD36 depletion in hMEC influences gene expression and insulin action: Cells were 424 425 treated with either control siRNA or anti CD36 siRNA. First, the resulting alterations in gene expression were determined by RNA seq (Fig. 5A). CD36 depletion associated with 426 427 increased expression of FGF1, insulin like growth factor 1 (IGF1), Jak3, PIK3 catalytic domain and various integrins (ITG) including ITGA11, ITGA4, ITGA5 and ITGB5. Integrins 428 429 regulate signaling by PI3K and growth factors (32). Overall, the above upregulated genes 430 function to promote glucose utilization and cell survival, either directly or through activation 431 of PI3K/AKT and growth factor signaling (32, 35).

We previously showed that CD36 expression in human derived primary muscle cells facilitates IR signaling and its depletion suppresses insulin activation of AKT (5). The hMEC were tested for insulin responsiveness and the effect of CD36 knockdown. The hMEC behaved like the human muscle cells; they responded to insulin with robust phosphorylation of the activating sites of AKT^{S473} and eNOS^{S1177}, and CD36 knockdown significantly suppressed insulin activation of both proteins (**Fig. 5B, C, D**).

438 Interaction of eNOS with Caveolin-1: In endothelial cells, Cav-1 interaction with 439 eNOS regulates eNOS activity and this interaction is enhanced by insulin (41, 42). CD36 440 resides in caveolae and can influence Cav-1 dynamics (28) so we examined whether CD36 it influences insulin regulation of the Cav-1/eNOS interaction. Immunoprecipitation of Cav-441 442 1 from control and CD36 depleted hMEC showed, consistent with previous findings, that 443 insulin enhances interaction of Cav-1 with eNOS in control cells (41). Interestingly, CD36 444 depletion eliminated the effect of insulin on Cav-1/eNOS interaction (Fig. 5E). In addition, 445 consistent with CD36 knockdown acting to suppress insulin activation of eNOS, insulin-446 stimulated NO production was simultaneously reduced (Fig. 5F).

447 Together these data support influence of endothelial CD36 on insulin-induced eNOS activation and NO production and suggest that CD36 depletion associates with endothelial 448 449 insulin resistance and reduced NO availability. These data are consistent with the lack of 450 insulin induced increase in microvascular volume that is observed in G-allele carriers by 451 the hyperinsulinemic clamps (Fig. 4A) and the defect in arterial flow mediated dilation and 452 low cGMP levels previously described in these individuals (9). They are also consistent with 453 the observed vascular dysfunction; reduced capillary perfusion and vessel compliance, in 454 *Cd36^{-/-}* mice (**Fig. 3 E, F, G**).

455 Defects in microvascular insulin action and NO production and reduced endothelial 456 compliance are a hallmark of metabolic disease and thought to be involved in etiology of 457 T2D (43, 44). Previously we applied Predixcan analysis to a large patient sample in the 458 BioVu database of Vanderbilt University and documented that genetically determined low 459 CD36 mRNA in muscle or heart strongly associates with incidence of type 2 diabetes (T2D) 460 and its complications (5). PrediXcan estimates for GWAS samples the Genetically 461 Regulated eXpression (GReX) of a gene in specific tissues and uses GReX to identify 462 genes associated with disease risk (45, 46). We again used PrediXcan to test whether the 463 association holds if the analysis considers CD36 mRNA in blood or arteries. We found that low vascular CD36 levels associates with T2D and its renal, ophthalmic, and neurological 464 465 manifestations (Table 2).

466 **Discussion**

467 The coding CD36 SNP rs3211938 (T/G) is the major cause of CD36 deficiency in African Americans with an incidence of 9-12% for homozygous (G/G) and 20-25% for heterozygous 468 469 (G/T) (9, 10). In Japanese, CD36 deficiency has a frequency of 3% for homozygous and 470 6% for heterozygous (14). Total deficiency is low in Caucasians (0.3%) but SNPs that 471 reduce CD36 expression are relatively common (5-40%) (6, 11). CD36 SNPs often 472 associate with high circulating lipids, FA (6, 9) and chylomicron remnants (11, 47) and with 473 risk of metabolic syndrome (10, 48) and T2D coronary heart disease (6). We identified in 474 the BioVu patient biobank association of low heart and muscle CD36 mRNA with T2D renal, 475 ophthalmic and neurologic complications (5) and now confirm this association for low blood 476 and vascular CD36 (Table 2). Mechanisms underlying CD36 link to T2D are largely unclear.

477 There is currently no data to support a link between CD36 deficiency and insulin resistance of glucose metabolism. A few studies in Japanese with CD36 deficiency 478 479 documented blood lipid abnormalities but provided no definitive answer related to presence 480 of insulin resistant glucose disposal (12, 49). In this study, our hyperinsulinemic euglycemic 481 clamps in individuals with partial CD36 deficiency (G-allele carriers) (9) and matched 482 controls document enhanced insulin stimulated glucose disposal in the CD36 deficient 483 group, like what is observed in CD36 deficient mice. The enhanced insulin stimulated 484 glucose disposal in G-allele carriers occurs without the insulin induced increase in 485 microvascular blood volume. The MVB increase which normally enhances insulin delivery 486 to muscle (19, 20) does not play a role in the improved insulin stimulated glucose disposal 487 of G-allele carriers. The lack of insulin MVB response suggests presence of selective 488 microvascular insulin resistance in G-allele carriers as compared to non-carriers (Fig. 4A). 489 This finding is consistent with the previous demonstration of impaired flow mediated dilation 490 of the brachial artery and low cGMP levels in these individuals, suggesting low NO 491 bioavailability (9). Our data with hMEC (Fig. 5) directly link insulin resistance to endothelial 492 dysfunction of the microvasculature. CD36 knockdown, blocks insulin signaling to AKT and 493 insulin activation of eNOS and NO release. This provides a plausible mechanism for the 494 endothelial dysfunction present in humans with partial CD36 deficiency and would apply to 495 the reduced capillary perfusion and vessel compliance observed in $Cd36^{-/-}$ mice. 496 Importantly in CD36 deficiency the microvascular dysfunction did not cause insulin 497 resistance of glucose metabolism as would have been expected and as previously shown 498 in obese mice (50). The major difference in the case of CD36 deficiency is that it reduces FA uptake and is critical endothelial FA transcytosis (16, 28). Infusion of intralipid in our 499 500 study blunted the effect of insulin to increase MVB in non-carriers and reduced GIR in both 501 groups (Fig. 3B, C, D) indicating that partial CD36 deficiency does not protect against 502 excess intake. CD36 deficiency protects from the muscle insulin resistance induced by high 503 fat feeding (Fig. 2) (15). The lack of protection in humans could reflect the difference 504 between effects of total (mice) versus partial CD36 deficiency (G-allele carriers). However, 505 uptake of FA from chylomicrons is not mediated by CD36 (51, 52) and the same is likely to 506 apply to lipid emulsions infused along with heparin. In both cases lipolysis results in 507 excessively high FA levels at the endothelial interface and under such conditions FA uptake 508 is independent of CD36.

Our studies in Cd36^{-/-} mice provide data that parallel and support interpretation of 509 510 the findings in CD36 deficient humans. Enhanced insulin stimulated glucose uptake by 511 heart, various muscles and adipose tissues, and better suppression of endogenous glucose production by the liver are observed in $Cd36^{-/-}$ mice as compared to controls (**Figs. 1, 2**). 512 513 The enhancement in insulin action on glucose metabolism in muscle, liver and adipose 514 tissue of Cd36^{-/-} mice occurs despite a reduced capillary perfusion area and impaired vessel 515 compliance in these mice. The mice studies, like the human studies indicate that enhanced 516 capillary insulin delivery does not contribute to the improvement in insulin stimulated 517 glucose disposal. The data in mice suggest an important role for the adaptive transcriptional 518 remodeling of muscle in CD36 deficiency, where there is upregulated expression of GLUT4. 519 of PI3K/AKT and of enzymes of glucose utilization. In addition, the primary receptors for 520 two potent stimulators of muscle glucose uptake FGF-R1 and IGF-R1 are upregulated. 521 Interestingly, expression of the corresponding growth factors FGF1 and IGF1 is increased 522 in hMEC after CD36 knockdown, as compared to the low levels in cells treated with control 523 siRNA. CD36 antagonizes effects of growth and pro-angiogenic factors in EC (53). As its 524 deletion relieves this negative regulation, one can speculate that this increases endothelial 525 release of FGF1 and IGF-1 by CD36 deficient EC. Interaction of the growth factors with 526 their receptors in muscle would enhance glucose uptake and utilization.

527 The endothelium can regulate insulin-stimulated glucose disposal through 528 controlling insulin delivery to muscle (20), through release of NO (54, 55) and other 529 bioactive molecules (56) or the secretion of exosomes (28). Endothelial insulin resistance 530 is thought to be a precursor of muscle insulin resistance and the reduced NO availability 531 was implicated in driving insulin resistance of glucose metabolism in obese mice (50). 532 However, an opposite outcome like the one we describe in G-allele carriers was reported 533 in a recent study where inducing EC specific insulin resistance by disabling endothelial IR 534 and IGF-1R, enhanced muscle and fat insulin sensitivity (57). Increased expression of 535 NADPH oxidase 4 and consequent endothelial release of peroxide were suggested as 536 mediators. We do not observe increased NADPH oxidase 4 expression in CD36 deficient 537 EC, although we do not rule out its potential contribution. In the case of CD36 deficiency 538 we believe the effect might be linked to the absence of endothelial FA uptake. Endothelial 539 cell CD36 controls delivery of circulating FA to heart and muscle (16) through a transfer 540 mechanism that involves generation and secretion of CD36-containing FA-exosomes.

These EC derived exosomes can regulate muscle gene expression and metabolic adaptation (28). The exosome cargo and how it is altered in obesity or with excess fat intake will need to be examined as this might shed more light on the role of the endothelium in regulating insulin resistance.

In conclusion partial CD36 deficiency in humans, as observed in CD36 deficient mice increases insulin-stimulated glucose utilization, which energetically compensates for the suppressed FA uptake. Some limitations apply to our hyperinsulinemic euglycemic studies in humans notably the relatively small number of subjects studied (13 controls and 8 Gallele carriers). However, study participants underwent in-depth metabolic phenotyping before matching the cohorts. The small difference in weight between the cohorts is another limitation but it was addressed through adjusting the glucose infusion rate by weight.

552 The evidence provided in this study support the role of CD36 deficiency in 553 microvascular insulin resistance and reduced NO bioavailability (Fig. 4 and 5). Although 554 this impairment does not associate with reduced muscle glucose disposal and instead 555 enhances it, the long-term effects of this dysfunction within the context of obesity are likely 556 to be detrimental and could play an important role in the etiology of T2D complications. 557 Genetic data associate low CD36 mRNA in various tissues including heart, skeletal muscle 558 (5) and endothelium (Table 2) with T2D renal, ophthalmic and neurologic complications, which often reflect vascular impairments. A common CD36 haplotype in Caucasians 559 560 associates with coronary heart disease in diabetics (6). The defect in NO production in 561 CD36 deficiency identified in both CD36 deficient mice and humans is likely to contribute 562 to etiology of the microvascular complications of T2D and could be targeted to prevent or 563 mitigate these abnormalities.

Acknowledgments: We acknowledge support of National Institute of Health RO1DK111175
 (NAA, CAS, NNA), NHLBI R01HL157584 (CAS), NHLBI R01 HL045095 (IJG, NAA) and
 Clinical Translational Science Award (CTSA) 5UL1TR002243-03 (CAS), and assistance of
 Vanderbilt Institute for Clinical and Translational Sciences and Washington University
 Nutrition and Obesity Center (NORC, NIH P30 DK056341).

569

570 **Figure legends**:

571 Figure 1. CD36 deletion in mice improves insulin sensitivity and the glucose 572 metabolic index. Hyperinsulinemic-euglycemic clamps were performed in awake, non-573 restrained wildtype (WT) and Cd36^{-/-} mice. A. Body weight. B. Fasting and clamp insulin 574 was similar in both genotypes. C. Reduced fasting glucose in Cd36^{-/-} but similar blood 575 glucose levels in WT and Cd36^{-/-} mice during the clamp. **D.** Higher glucose infusion rates were needed to maintain euglycemia in Cd36^{-/-} mice compared to WT. E. Glucose 576 577 disappearance rates are higher in Cd36^{-/-} mice during the clamp. **F.** Insulin more effectively 578 suppresses endogenous glucose production in Cd36^{-/-} mice. **G and H**. Glucose metabolic 579 index in superficial vastus muscle (SVL), soleus, (SubQ AT), and brown adipose tissue 580 (BAT) in Cd36^{-/-} mice as compared to WT mice. Gastrocnemius (gastroc), peri-gonadal 581 adipose tissue (PG AT), and heart glucose metabolic index were elevated but differences 582 did not reach significance. As expected, brain glucose metabolic index was equivalent in 583 WT and $Cd36^{-/-}$ mice. Data are mean ± SE. n=5-7 *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 584

585 Figure 2. Insulin signaling is enhanced in muscle of Cd36^{-/-} mice. A. Intraperitoneal 586 glucose tolerance test (IGTT) in 5h fasted mice fed a chow diet. B. IGTT and C. insulin 587 sensitivity test in mice fed a high fat diet for 12 weeks. D. Muscle insulin sensitivity: WT 588 mice and $Cd36^{-/-}$ mice were fasted for 5h, then insulin (7.5 IU/kg) was given 589 intraperitoneally, the gastrocnemius was harvested 15 min later and probed for CD36, 590 pAKT and total AKT. E. Levels of insulin phosphorylated AKT at serine 473 and F. threonine 591 308, both adjusted for total AKT. N=5-6 mice group. G. Altered expression of genes related 592 to insulin signaling and glucose utilization shown as fold change of levels in $Cd36^{-/2}$ as 593 compared to WT controls (n=4 per group).

Figure 3. CD36 deletion on trans-endothelial insulin efflux kinetics in capillaries of skeletal muscle following a 2 U/kg bolus of insulin-647 in WT *Cd36^{-/-}* mice. **A**. Capillary plasma INS-647 fluorescence. **B.** Interstitial INS-647 fluorescence. The interstitial space is defined as the region extending 1-3 µm from the capillary wall. **C.** Ratio of plasma/interstitial INS-647 intensity. **D.** The exponential decay constant of plasma/interstitial INS-647 gradient decay. **E.** Capillary diameter. **F.** Perfused capillary surface area, capillary diameter and perfused surface area measured using 2 MDa tetramethylrhodamine-dextran

fluorescence as a vascular marker. The microvascular perfused area determined in the kidney using FASL-MRI in WT and Cd36^{-/-} mice. Both measures of the perfused microvascular area yielded a ~30% reduction in *Cd36^{-/-}* mice compared to WT mice. Data are mean \pm SE. n=5 per group. *p<0.05, **p<0.01.

605 Figure 4. Hyperinsulinemic euglycemic clamp in individuals carrying the G allele 606 (G/T) of CD36 SNP rs3211938 with partial CD36 deficiency versus non-carriers 607 controls (T/T). Participants received 0.9% standard saline infusion (45ml/h) for 6 hours, 608 and during the last three hours, a hyperinsulinemic-euglycemic (HIE) clamp. Insulin was infused at a rate of 80 mU·m⁻²·min⁻¹ for 5 min followed by 40 mU·m⁻²·min⁻¹ for the remainder 609 610 of the study. A. Upper panel: Effect of insulin on microvascular blood volume index (MBVi). 611 Middle panel: Glucose infusion rate (GIR). Bottom panel: Circulating insulin levels were 612 similar G-allele carriers and noncarriers during basal and clamp periods. B. Participants 613 receives a 6-hour IV infusion of 20% Intralipid instead of saline before the three-hour HIE. 614 Upper panel: MVBi, middle panel: GIR, bottom panel: circulating insulin levels in basal and 615 clamp.

616 Figure 5. Figure 5. CD36 regulates insulin signaling in primary derived human 617 microvascular cells (hMEC). A. Alterations in genes related to PI3K-Insulin signaling in 618 control hMEC (Ctrl, treated with scrambled siRNA) and CD36KD (KD, hMEC treated with anti-CD36 siRNA). B. Western blots of hMEC, Control (CtrlKD) and CD36KD showing effect 619 620 of insulin (100nM, 5min) on phosphorylation of AKT and eNOS. C and D. Densitometry 621 analysis of pAKT/total AKT and of p-eNOS/total eNOS (n=3 p<0.05). E. CD36 knockdown 622 on insulin-dependent interaction of Cav-1 and eNOS. Western blot is representative of 623 three independent experiments. F. CD36 regulation of NO production. Ctrl and CD36KD 624 hMEC were serum starved and subjected to insulin stimulation (100nM, 5min). n=4, assays. *p<0.05, ****p<0.005, ****p<0.0001). 625

- 626
- 627
- 628
- 629
- 630

Table 1. Demographic characteristics of study participantsValues are means \pm standard error of the mean. P values were 2generated with Student's t-test.633

	G-allele N-8	Non-carriers N-13		634
Ago vooro	<u>0-alicic</u> N=0	$\frac{11011-02111013}{24 \times 24}$	0.040*	635
Age, years	42 ± 2.0	34 ± 2.1	0.019	636
Gender(m/f)	3/5	3/10		637
Weight, kg	79 ± 2.9	89 ± 3.8	0.083	057
Glucose, mg/dL	81 ± 3.8	86 ± 5.4	0.511	638
Cholesterol ma/dl	180 + 13 1	177 + 6 7	0 821	639
	100 ± 10.1	FA 0.5	0.021	640
HDL, mg/dL	51 ± 4.88	54 ± 3.5	0.567	641
LDL, mg/dL	106 ± 12.8	106 ± 6.1	0.986	011
Triglycerides, mg/dL	116 ± 26.1	83 ± 10.9	0.189	642
SBP, mm Hg	124 ± 4.7	120 ± 2.4	0.349	643
OBP, mm Hg	75 ± 3.6	77 ± 2.5	0.857	644
HR, bpm	78 ± 7.5	68 ± 3.7	0.206	645
				646

647

Table 2: Association of genetically determined low endothelial CD36 expression

649 with T2D status and complications.

Tissue CD36	Effect	p-value	T2D and complications
Whole Blood	-4.323	0.000015	T2D + renal manifestations
Artery -Tibial	-4.058	0.00005	T2D + renal manifestations
Artery -Tibial	-3.506	0.00045	T2D + ophthalmic manifestations
Artery -Tibial	-3.434	0.00059	T2D + neurological manifestations

650 CD36 contribution to T2D risk was evaluated using PrediXcan analysis (45). The genetically 651 determined component of CD36 expression was estimated from gene expression 652 imputation trained with reference transcriptome data (N = 44 tissues, 449 donors, version 653 6p) from the Genotype-Tissue Expression (GTEx) Consortium. Analysis was applied to 654 4702 total patients of European ancestry with 1484 patients with T2D, in the BioVU 655 database (58) of Vanderbilt University where health records are tied to a DNA biobank. Samples were genotyped, Illumina 660K, and genotype imputation used 1000 Genomes 656 Project (59) as reference. For replication of CD36 gene level association with T2D risk, we 657 used GWAS meta-analysis data on HOMA-IR from the MAGIC Consortium (60) and applied 658 659 PrediXcan to GWAS summary statistics. The replication data set had 37037 participants of 660 European ancestry.

- 661
- 662
- 663
- 664
- 665
- 666



668

Figure 1: CD36 deletion in mice improves insulin sensitivity and the glucose 669 670 metabolic index. Hyperinsulinemic-euglycemic clamps were performed in awake, nonrestrained wildtype (WT) and Cd36^{-/-} mice. A. Body weight. B. Fasting and clamp insulin 671 was similar in both genotypes. C. Reduced fasting glucose in $Cd36^{-/-}$ but similar blood 672 673 glucose levels in WT and $Cd36^{-1}$ mice during the clamp. **D**. Higher glucose infusion rates were needed to maintain euglycemia in $Cd36^{-/-}$ mice compared to WT. E. Glucose 674 disappearance rates are higher in $Cd36^{-/-}$ mice during the clamp. **F**. Insulin more effectively 675 suppresses endogenous glucose production in Cd36^{-/-} mice. G-H. Glucose metabolic index 676 in superficial vastus muscle (SVL), soleus, subcutaneous (SubQ AT), and brown adipose 677 tissue (BAT) in Cd36^{-/-} mice as compared to WT mice. Gastrocnemius (gastroc), peri-678 679 gonadal adipose tissue (PG AT), and heart glucose metabolic index were elevated but 680 differences did not reach significance. As expected, brain glucose metabolic index was equivalent in WT and Cd36^{-/-} mice. Data are mean \pm SE. n=5-7 *p<0.05, **p<0.01, 681 ***p<0.001, ****p<0.0001. 682



Figure 2: Enhanced Insulin signaling in muscle of Cd36^{-/-} mice. A. Intraperitoneal (IP) 685 glucose tolerance test (IPGTT) in 5h fasted mice showing enhanced glucose disposal in 686 Cd36^{-/-} as compared to WT mice. B. IPGTT, and C. Insulin sensitivity test in mice after 687 feeding a high fat diet (HFD) showing glucose intolerance in WT mice, while Cd36^{-/-} mice 688 are protected. N=5-6 per group. **D.** 5h fasted $Cd36^{-/-}$ mice and WT controls were given 689 690 insulin (7.5 IU/kg) IP and the gastrocnemius muscles were harvested 15 min later and processed for Western blots. Shown are signals for CD36, pAKT^{S473} and total AKT. E-F. 691 Levels of insulin phosphorylated AKT (S473 and T308) adjusted for total AKT. G-H. 692 Enhanced S6 phosphorylation in gastrocnemius of $Cd36^{-/-}$ mice as compared to WT mice 693 and quantification of levels adjusted for total S6. I. Altered expression of genes related to 694 695 insulin action and glucose metabolism in muscle of WT and $Cd36^{-/-}$ mice, n=3 per group. 696 *p<0.05, **p<0.01, ****p<0.0001.

697



698

699

700 Figure 3: Trans-endothelial insulin efflux in muscle and the microvascular perfused 701 area. WT and Cd36^{-/-} mice were given a 2 U/kg bolus of insulin-647. A. Capillary plasma INS-647 fluorescence **B.** INS-647 in interstitial space extending 1-3 µm from capillary wall. 702 703 C. Plasma/interstitial INS-647 intensity. D. Exponential decay constant of plasma/interstitial 704 INS-647 gradient. E. Capillary diameter and F. Perfused capillary surface, both assessed 705 with 2 MDa tetramethylrhodamine-dextran fluorescence, a vascular marker, show ~30% reduction in $Cd36^{-/-}$ mice compared to WT mice. Data are means ± SE. n=5 per group. G. 706 707 Intravascular pressure of carotid artery (left panel) and aorta (right panel) from Cd36^{-/-} mice 708 compared to WT mice (n=3/genotype). The vessels were mounted in saline on a pressure 709 arteriograph, pressurized and longitudinally stretched three times to *in vivo* length before 710 data capture. *p<0.05, **p<0.01.



734 Figure. Hyperinsulinemic euglycemic clamp in individuals carrying the G allele 735 (G/T) of CD36 SNP rs3211938 with partial CD36 deficiency versus non-carriers controls (T/T). Participants received standard saline infusion (45ml/h) for 6 h, and a 736 737 hyperinsulinemic-euglycemic (HIE) clamp during the last three h. Insulin was infused at a rate of 80 mU·m⁻²·min⁻¹ for 5 min followed by 40 mU·m⁻²·min⁻¹ for the rest of the study. **A.** 738 739 Upper panel: Effect of insulin on microvascular blood volume index (MBVi). Middle panel: 740 Glucose infusion rate (GIR). Bottom panel: Circulating insulin levels were similar for G-741 allele carriers and noncarriers during basal and clamp periods. B. Participants received a 742 6-hour IV infusion of 20% Intralipid before the three-hour HIE. Upper panel: MVBi, middle panel: GIR. bottom panel: circulating insulin levels. *P=0.05 743



744

745 Figure 5. CD36 regulates insulin signaling in primary derived human microvascular cells (hMEC). A. Alterations in genes related to PI3K-Insulin signaling in control hMEC 746 747 (Ctrl, treated with scrambled siRNA) and CD36KD (KD, hMEC treated with anti-CD36 748 siRNA). B. Western blots of hMEC. Control (CtrlKD) and CD36KD showing effect of insulin 749 (100nM, 5min) on phosphorylation of AKT and eNOS. C and D. Densitometry analysis of 750 pAKT/total AKT and of p-eNOS/total eNOS (n=3 p<0.05). E. CD36 knockdown on insulin-751 dependent interaction of Cav-1 and eNOS. Western blot is representative of three 752 independent experiments. F. CD36 regulation of NO production. Ctrl and CD36KD hMEC 753 were serum starved and subjected to insulin stimulation (100nM, 5min). n=4, assays. 754 *p<0.05, ****p<0.005.

- 755
- 756
- 757
- 758
- 759

760 References

- Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, et al. Identification of Cd36 (Fat) as an insulinresistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. *Nat Genet.* 1999;21(1):76-83.
- Pravenec M, Landa V, Zidek V, Musilova A, Kren V, Kazdova L, Aitman TJ, Glazier AM,
 Ibrahimi A, Abumrad NA, et al. Transgenic rescue of defective Cd36 ameliorates insulin
 resistance in spontaneously hypertensive rats. *Nat Genet.* 2001;27(2):156-8.
- Corpeleijn E, van der Kallen CJ, Kruijshoop M, Magagnin MG, de Bruin TW, Feskens EJ,
 Saris WH, and Blaak EE. Direct association of a promoter polymorphism in the CD36/FAT
 fatty acid transporter gene with Type 2 diabetes mellitus and insulin resistance. *Diabet Med.* 2006;23(8):907-11.
- 4. Lepretre F, Vasseur F, Vaxillaire M, Scherer PE, Ali S, Linton K, Aitman T, and Froguel P.
 A CD36 nonsense mutation associated with insulin resistance and familial type 2 diabetes.
 Hum Mutat. 2004;24(1):104.
- 5. Samovski D, Dhule P, Pietka T, Jacome-Sosa M, Penrose E, Son NH, Flynn CR, Shoghi
 KI, Hyrc KL, Goldberg IJ, et al. Regulation of Insulin Receptor Pathway and Glucose
 Metabolism by CD36 Signaling. *Diabetes.* 2018;67(7):1272-84.
- Ma X, Bacci S, Mlynarski W, Gottardo L, Soccio T, Menzaghi C, Iori E, Lager RA, Shroff
 AR, Gervino EV, et al. A common haplotype at the CD36 locus is associated with high free
 fatty acid levels and increased cardiovascular risk in Caucasians. *Hum Mol Genet.*2004;13(19):2197-205.
- 782 7. Aitman TJ, Cooper LD, Norsworthy PJ, Wahid FN, Gray JK, Curtis BR, McKeigue PM,
 783 Kwiatkowski D, Greenwood BM, Snow RW, et al. Malaria susceptibility and CD36
 784 mutation. *Nature*. 2000;405(6790):1015-6.
- 8. Lee K, Godeau B, Fromont P, Plonquet A, Debili N, Bachir D, Reviron D, Gourin J,
 Fernandez E, Galacteros F, et al. CD36 deficiency is frequent and can cause platelet
 immunization in Africans. *Transfusion.* 1999;39(8):873-9.
- Shibao CA, Celedonio JE, Ramirez CE, Love-Gregory L, Arnold AC, Choi L, Okamoto LE,
 Gamboa A, Biaggioni I, Abumrad NN, et al. A Common CD36 Variant Influences
 Endothelial Function and Response to Treatment with Phosphodiesterase 5 Inhibition. J *Clin Endocrinol Metab.* 2016;101(7):2751-8.
- 10. Love-Gregory L, Sherva R, Sun L, Wasson J, Schappe T, Doria A, Rao DC, Hunt SC,
 Klein S, Neuman RJ, et al. Variants in the CD36 gene associate with the metabolic
 syndrome and high-density lipoprotein cholesterol. *Hum Mol Genet.* 2008;17(11):1695704.
- Love-Gregory L, Kraja AT, Allum F, Aslibekyan S, Hedman AK, Duan Y, Borecki IB, Arnett
 DK, McCarthy MI, Deloukas P, et al. Higher chylomicron remnants and LDL particle
 numbers associate with CD36 SNPs and DNA methylation sites that reduce CD36. *J Lipid Res.* 2016;57(12):2176-84.
- 80012.Miyaoka K, Kuwasako T, Hirano K, Nozaki S, Yamashita S, and Matsuzawa Y. CD36801deficiency associated with insulin resistance. Lancet. 2001;357(9257):686-7.
- 80213.Furuhashi M, Ura N, Nakata T, and Shimamoto K. Insulin sensitivity and lipid metabolism803in human CD36 deficiency. Diabetes Care. 2003;26(2):471-4.
- 80414.Kajihara S, Hisatomi A, Ogawa Y, Yasutake T, Yoshimura T, Hara T, Mizuta T, Ozaki I,805Iwamoto N, and Yamamoto K. Association of the Pro90Ser CD36 mutation with elevated806free fatty acid concentrations but not with insulin resistance syndrome in Japanese. Clin807Chim Acta. 2001;314(1-2):125-30.
- Hajri T, Han XX, Bonen A, and Abumrad NA. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. *J Clin Invest.*2002;109(10):1381-9.

811 16. Son NH, Basu D, Samovski D, Pietka TA, Peche VS, Willecke F, Fang X, Yu SQ, Scerbo 812 D, Chang HR, et al. Endothelial cell CD36 optimizes tissue fatty acid uptake. J Clin Invest. 813 2018;128(10):4329-42. 814 17. Laakso M, Edelman SV, Brechtel G, and Baron AD. Decreased effect of insulin to 815 stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin 816 resistance. J Clin Invest. 1990;85(6):1844-52. 817 18. Clerk LH, Vincent MA, Lindner JR, Clark MG, Rattigan S, and Barrett EJ. The vasodilatory 818 actions of insulin on resistance and terminal arterioles and their impact on muscle glucose 819 uptake. Diabetes Metab Res Rev. 2004;20(1):3-12. 820 19. Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, and Barrett EJ. 821 Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose 822 uptake in vivo. *Diabetes*. 2004;53(6):1418-23. 823 20. Williams IM, and Wasserman DH. Capillary Endothelial Insulin Transport: The Rate-824 limiting Step for Insulin-stimulated Glucose Uptake. Endocrinology. 2022;163(2). 825 21. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, and Yki-Jarvinen H. 826 Marked resistance of the ability of insulin to decrease arterial stiffness characterizes 827 human obesity. Diabetes. 1999;48(4):821-7. 828 22. Knutsen RH, Beeman SC, Broekelmann TJ, Liu D, Tsang KM, Kovacs A, Ye L, Danback 829 JR, Watson A, Wardlaw A, et al. Minoxidil improves vascular compliance, restores 830 cerebral blood flow, and alters extracellular matrix gene expression in a model of chronic 831 vascular stiffness. Am J Physiol Heart Circ Physiol. 2018;315(1):H18-H32. 832 23. Wagenseil JE, Nerurkar NL, Knutsen RH, Okamoto RJ, Li DY, and Mecham RP. Effects of 833 elastin haploinsufficiency on the mechanical behavior of mouse arteries. Am J Physiol 834 Heart Circ Physiol. 2005;289(3):H1209-17. Williams IM, Valenzuela FA, Kahl SD, Ramkrishna D, Mezo AR, Young JD, Wells KS, and 835 24. 836 Wasserman DH. Insulin exits skeletal muscle capillaries by fluid-phase transport. J Clin 837 Invest. 2018;128(2):699-714. 838 25. Avala JE, Bracy DP, Malabanan C, James FD, Ansari T, Fueger PT, McGuinness OP, and 839 Wasserman DH. Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice. J 840 Vis Exp. 201157). 841 26. Berglund ED, Li CY, Poffenberger G, Ayala JE, Fueger PT, Willis SE, Jewell MM, Powers 842 AC, and Wasserman DH. Glucose metabolism in vivo in four commonly used inbred 843 mouse strains. Diabetes. 2008;57(7):1790-9. 844 27. Lantier L, Williams AS, Williams IM, Yang KK, Bracy DP, Goelzer M, James FD, Gius D, 845 and Wasserman DH. SIRT3 Is Crucial for Maintaining Skeletal Muscle Insulin Action and 846 Protects Against Severe Insulin Resistance in High-Fat-Fed Mice. Diabetes. 847 2015;64(9):3081-92. 848 Peche VS, Pietka TA, Jacome-Sosa M, Samovski D, Palacios H, Chatterjee-Basu G, 28. 849 Dudley AC, Beatty W, Meyer GA, Goldberg IJ, et al. Endothelial cell CD36 regulates 850 membrane ceramide formation, exosome fatty acid transfer and circulating fatty acid 851 levels. Nat Commun. 2023;14(1):4029. 852 29. Hajri T, Hall AM, Jensen DR, Pietka TA, Drover VA, Tao H, Eckel R, and Abumrad NA. 853 CD36-facilitated fatty acid uptake inhibits leptin production and signaling in adipose tissue. 854 Diabetes. 2007;56(7):1872-80. 855 30. Minchenko O, Opentanova I, and Caro J. Hypoxic regulation of the 6-phosphofructo-2-856 kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS 857 Lett. 2003;554(3):264-70. 858 31. Ying L, Wang L, Guo K, Hou Y, Li N, Wang S, Liu X, Zhao Q, Zhou J, Zhao L, et al. 859 Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects. Nat 860 Commun. 2021;12(1):7256.

- 861 32. Grassian AR, Coloff JL, and Brugge JS. Extracellular matrix regulation of metabolism and 862 implications for tumorigenesis. Cold Spring Harb Symp Quant Biol. 2011;76(313-24. 863 Bugiardini E, Nunes AM, Oliveira-Santos A, Dagda M, Fontelonga TM, Barraza-Flores P, 33. 864 Pittman AM, Morrow JM, Parton M, Houlden H, et al. Integrin alpha7 Mutations Are 865 Associated With Adult-Onset Cardiac Dysfunction in Humans and Mice. J Am Heart 866 Assoc. 2022;11(23):e026494. 867 34. Vachon PH. Xu H. Liu L. Loechel F. Havashi Y. Arahata K. Reed JC. Wewer UM. and 868 Engvall E. Integrins (alpha7beta1) in muscle function and survival. Disrupted expression in 869 merosin-deficient congenital muscular dystrophy. J Clin Invest. 1997;100(7):1870-81. 870 35. Krolopp JE, Thornton SM, and Abbott MJ. IL-15 Activates the Jak3/STAT3 Signaling 871 Pathway to Mediate Glucose Uptake in Skeletal Muscle Cells. Front Physiol. 2016;7(626. 872 36. Kwong KK, Chesler DA, Weisskoff RM, Donahue KM, Davis TL, Ostergaard L, Campbell 873 TA, and Rosen BR. MR perfusion studies with T1-weighted echo planar imaging. Magn 874 Reson Med. 1995;34(6):878-87.
- 875 37. Beeman SC, Cullen-McEwen LA, Puelles VG, Zhang M, Wu T, Baldelomar EJ, Dowling J,
 876 Charlton JR, Forbes MS, Ng A, et al. MRI-based glomerular morphology and pathology in
 877 whole human kidneys. *Am J Physiol Renal Physiol.* 2014;306(11):F1381-90.
- 878 38. Love-Gregory L, Sherva R, Schappe T, Qi JS, McCrea J, Klein S, Connelly MA, and
 879 Abumrad NA. Common CD36 SNPs reduce protein expression and may contribute to a
 880 protective atherogenic profile. *Hum Mol Genet.* 2011;20(1):193-201.
- Monti LD, Barlassina C, Citterio L, Galluccio E, Berzuini C, Setola E, Valsecchi G, Lucotti
 P, Pozza G, Bernardinelli L, et al. Endothelial nitric oxide synthase polymorphisms are
 associated with type 2 diabetes and the insulin resistance syndrome. *Diabetes*.
 2003;52(5):1270-5.
- Nolan DJ, Ginsberg M, Israely E, Palikuqi B, Poulos MG, James D, Ding BS, Schachterle
 W, Liu Y, Rosenwaks Z, et al. Molecular signatures of tissue-specific microvascular
 endothelial cell heterogeneity in organ maintenance and regeneration. *Dev Cell.*2013;26(2):204-19.
- 41. Chen Z, S DSO, Zimnicka AM, Jiang Y, Sharma T, Chen S, Lazarov O, Bonini MG, Haus
 JM, and Minshall RD. Reciprocal regulation of eNOS and caveolin-1 functions in
 endothelial cells. *Mol Biol Cell*. 2018;29(10):1190-202.
- Wang H, Wang AX, Liu Z, Chai W, and Barrett EJ. The trafficking/interaction of eNOS and caveolin-1 induced by insulin modulates endothelial nitric oxide production. *Mol Endocrinol.* 2009;23(10):1613-23.
- 43. Hasan SS, and Fischer A. The Endothelium: An Active Regulator of Lipid and Glucose
 Homeostasis. *Trends Cell Biol.* 2021;31(1):37-49.
- 44. Wasserman DH, Wang TJ, and Brown NJ. The Vasculature in Prediabetes. *Circ Res.*2018;122(8):1135-50.
- 89945.Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, Eyler900AE, Denny JC, Consortium GT, Nicolae DL, et al. A gene-based association method for901mapping traits using reference transcriptome data. Nat Genet. 2015;47(9):1091-8.
- 46. Hale AT, Bastarache L, Morales DM, Wellons JC, 3rd, Limbrick DD, Jr., and Gamazon ER.
 Multi-omic analysis elucidates the genetic basis of hydrocephalus. *Cell Rep.*2021;35(5):109085.
- Masuda D, Hirano K, Oku H, Sandoval JC, Kawase R, Yuasa-Kawase M, Yamashita Y,
 Takada M, Tsubakio-Yamamoto K, Tochino Y, et al. Chylomicron remnants are increased
 in the postprandial state in CD36 deficiency. *J Lipid Res.* 2009;50(5):999-1011.
- 48. Farook VS, Puppala S, Schneider J, Fowler SP, Chittoor G, Dyer TD, Allayee H, Cole SA,
 Arya R, Black MH, et al. Metabolic syndrome is linked to chromosome 7q21 and
 associated with genetic variants in CD36 and GNAT3 in Mexican Americans. *Obesity*(Silver Spring). 2012;20(10):2083-92.

- 912 49. Yanai H, Chiba H, Morimoto M, Jamieson GA, and Matsuno K. Type I CD36 deficiency in 913 humans is not associated with insulin resistance syndrome. *Thromb Haemost.* 914 2000;83(5):786.
- 50. Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, Inoue M, Itoh S,
 51. Takamoto I, Sasako T, et al. Impaired insulin signaling in endothelial cells reduces insulin52. induced glucose uptake by skeletal muscle. *Cell Metab.* 2011;13(3):294-307.
- 51. Cabodevilla AG, Tang S, Lee S, Mullick AE, Aleman JO, Hussain MM, Sessa WC,
 Abumrad NA, and Goldberg IJ. Eruptive xanthoma model reveals endothelial cells
 internalize and metabolize chylomicrons, leading to extravascular triglyceride
 accumulation. *J Clin Invest.* 2021;131(12).
- 52. Bharadwaj KG, Hiyama Y, Hu Y, Huggins LA, Ramakrishnan R, Abumrad NA, Shulman
 GI, Blaner WS, and Goldberg IJ. Chylomicron- and VLDL-derived lipids enter the heart
 through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty
 acid uptake. *J Biol Chem.* 2010;285(49):37976-86.
- 92653.Silverstein RL, Li W, Park YM, and Rahaman SO. Mechanisms of cell signaling by the927scavenger receptor CD36: implications in atherosclerosis and thrombosis. Trans Am Clin928Climatol Assoc. 2010;121(206-20.
- Higaki Y, Hirshman MF, Fujii N, and Goodyear LJ. Nitric oxide increases glucose uptake
 through a mechanism that is distinct from the insulin and contraction pathways in rat
 skeletal muscle. *Diabetes*. 2001;50(2):241-7.
- 932 55. Pappas G, Wilkinson ML, and Gow AJ. Nitric oxide regulation of cellular metabolism:
 933 Adaptive tuning of cellular energy. *Nitric Oxide.* 2023;131(8-17.
- 93456.Dransfeld O, Rakatzi I, Sasson S, Gruzman A, Schmitt M, Haussinger D, and Eckel J.935936Eicosanoids participate in the regulation of cardiac glucose transport by contribution to a
rearrangement of actin cytoskeletal elements. *Biochem J.* 2001;359(Pt 1):47-54.
- 57. Viswambharan H, Yuldasheva NY, Imrie H, Bridge K, Haywood NJ, Skromna A,
 938 Hemmings KE, Clark ER, Gatenby VK, Cordell P, et al. Novel Paracrine Action of
 939 Endothelium Enhances Glucose Uptake in Muscle and Fat. *Circ Res.* 2021;129(7):720-34.
- 840
 940
 941
 942
 942
 943
 944
 944
 944
 945
 945
 946
 947
 948
 948
 949
 949
 940
 941
 941
 941
 941
 942
 942
 942
 943
 944
 944
 944
 944
 945
 945
 946
 946
 947
 948
 948
 949
 949
 940
 941
 941
 941
 942
 942
 942
 942
 943
 944
 944
 944
 944
 945
 945
 946
 946
 947
 948
 948
 949
 949
 940
 941
 941
 941
 942
 942
 942
 942
 942
 943
 944
 944
 944
 944
 944
 944
 944
 945
 944
 945
 945
 946
 946
 947
 948
 948
 949
 949
 949
 949
 949
 940
 940
 941
 941
 942
 941
 942
 942
 942
 942
 944
 944
 944
 944
 944
 944
 944
 944
 944
 944
 944
 944
 944
 944
 944
 944
 944
 944
- 59. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO,
 Marchini JL, McCarthy S, McVean GA, et al. A global reference for human genetic
 variation. *Nature*. 2015;526(7571):68-74.
- Bupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E,
 Glazer NL, Bouatia-Naji N, Gloyn AL, et al. New genetic loci implicated in fasting glucose
 homeostasis and their impact on type 2 diabetes risk. *Nat Genet.* 2010;42(2):105-16.

949